Clomid vs Progesterone (Luteal Support): Side-Effect Profile Head-to-Head

What Are These Two Drugs Actually Doing?

Clomid and vaginal progesterone are not competitors in the way two antibiotics might be. They work at different moments in your menstrual cycle, and many women use both during the same treatment cycle. Understanding that distinction is the single most useful frame for comparing their side effects.

Clomiphene citrate (sold as Clomid or Serophene) is a selective estrogen-receptor modulator. It blocks estrogen receptors in the hypothalamus, which tricks your brain into secreting more FSH and LH, which in turn drives follicle development and, ideally, ovulation. It is taken orally, usually 50-150 mg per day for five days, starting on day 3 or day 5 of your cycle.

Vaginal micronized progesterone (brand names include Crinone 8%, Endometrin 100 mg, and compounded vaginal suppositories) is a bioidentical hormone. It replaces or supplements the progesterone that your corpus luteum normally produces after ovulation. Without adequate luteal-phase progesterone, the uterine lining cannot sustain implantation. A 2015 Cochrane review confirmed that progesterone supplementation significantly improves live-birth rates in women undergoing fresh IVF cycles, and the practice has been extended to ovulation-induction and IUI cycles as well.

Where Each Drug Sits in Your Cycle

• Days 3-7 (or 5-9): Clomiphene is taken to stimulate follicle growth.
• Day 10-14 (approximate): Ovulation occurs, often triggered by an hCG injection or occurring naturally.
• Days 15 onward (luteal phase): Vaginal progesterone is started, usually the evening of retrieval or the day after confirmed ovulation.
• If pregnancy is confirmed: Progesterone is typically continued. Clomiphene is stopped.

Clomid Side Effects: What Women Actually Report

Clomiphene's side effects are largely anti-estrogenic and occur during the five days you take the tablets, with some effects lingering through the peri-ovulatory window.

Hot Flushes and Vasomotor Symptoms

Hot flushes are the most commonly reported side effect, affecting roughly 10% of women taking standard 50 mg doses and a higher proportion at 100-150 mg. Because clomiphene blocks hypothalamic estrogen receptors, the same neural pathway responsible for menopausal hot flushes is activated. If you are in your mid-to-late reproductive years and already noticing occasional hot flushes, clomiphene can intensify them noticeably.

Cervical Mucus and Vaginal Dryness

This is the side effect that genuinely worries reproductive endocrinologists. Clomiphene's anti-estrogenic action thins cervical mucus, which can reduce sperm penetration even in cycles where ovulation is successfully induced. A comparison published in NEJM in 2014 (the PPCOSPP trial, n=750 women with PCOS) found that live-birth rates with clomiphene were 19.1% versus 27.5% with letrozole, a gap that is partly attributed to clomiphene's adverse endometrial and cervical-mucus effects despite similar ovulation rates. You may be ovulating on Clomid but still facing a thinner cervical-mucus environment for sperm to travel through.

Mood Changes and Emotional Symptoms

Many women describe irritability, tearfulness, or a general sense of emotional dysregulation during the five-day course. This mirrors the mood effects seen with other estrogen-receptor modulators. The data on clomiphene-specific mood effects are limited and have not been studied in large prospective trials specific to women. What is well-documented from tamoxifen trials (a related SERM) is that blocking central estrogen receptors does affect serotonergic signaling. This remains an area where female-specific trial data are thin, and much of the clinical guidance is extrapolated from general SERM pharmacology.

Visual Disturbances

Blurred vision, visual floaters, or light sensitivity occur in a small minority of women, estimated at 1-2% of treatment cycles. These are a reason to stop clomiphene immediately and contact your prescriber.

Ovarian Hyperstimulation and Cysts

Mild ovarian enlargement occurs in approximately 14% of clomiphene cycles. Severe ovarian hyperstimulation syndrome (OHSS) is rare with clomiphene alone but can occur when the drug is combined with injectable gonadotropins. Functional ovarian cysts may delay your next treatment cycle.

Multiple Pregnancy

The twin rate with clomiphene is approximately 5-8% of pregnancies, compared with a background rate of roughly 1-2%. Higher-order multiples are uncommon but possible.

Vaginal Progesterone Side Effects: What Women Actually Report

Vaginal progesterone's side effects fall into two categories: local (from the route of administration) and systemic (from progesterone itself).

Local Vaginal Side Effects

This is the category unique to vaginal progesterone that has no parallel with oral clomiphene. The gel, insert, or suppository leaves residue inside the vagina that accumulates over days. Women commonly describe a white or off-white discharge that can look like cottage cheese and is sometimes mistaken for a yeast infection. Crinone's prescribing information notes vaginal discharge in up to 22% of users and vaginal irritation or soreness in approximately 5-7%. Using a panty liner and rinsing externally (not internally) helps manage this.

Systemic Progesterone Effects: Fatigue and Drowsiness

Progesterone is converted to allopregnanolone, a neurosteroid that acts on GABA-A receptors, producing sedation. Vaginal dosing produces lower systemic levels than oral administration, which is one reason the vaginal route is preferred for luteal support. Even so, fatigue is reported by a meaningful proportion of women during the two-week wait. This can blur the line between a drug side effect and early pregnancy symptoms, which adds emotional complexity to an already anxious time.

Bloating and Breast Tenderness

Progesterone relaxes smooth muscle, slowing gastrointestinal transit and causing bloating. Breast tenderness is also common and again overlaps with early pregnancy symptoms. In the Cochrane review of luteal support in IVF, side-effect data across included trials were inconsistently reported, which reflects a genuine gap in the literature. Most trial authors tracked efficacy outcomes rather than patient-reported quality-of-life or side-effect outcomes.

Mood Effects

Progesterone metabolites affect GABA signaling, and some women describe a flattening of mood, mild depression, or anxiety during the luteal phase. Women with a history of premenstrual dysphoric disorder (PMDD) or postpartum depression may be more sensitive to exogenous progesterone. This is not a reason to avoid luteal support, but it is worth discussing with your clinician so you can monitor your mood during treatment.

What Vaginal Progesterone Does Not Cause

Vaginal progesterone does not cause hot flushes. It does not thin cervical mucus (the luteal phase is past the point where cervical mucus matters for conception). It does not cause visual disturbances. The side-effect profile is meaningfully different from clomiphene's, and the two drugs' adverse events do not compound each other in a straightforward additive way.

Side-by-Side Comparison

| Side Effect | Clomiphene (Clomid) | Vaginal Progesterone | |---|---|---| | Hot flushes / vasomotor | Common (approx. 10%+) | No | | Cervical mucus thinning | Yes, anti-estrogenic effect | No (post-ovulatory) | | Mood changes / irritability | Yes, reported frequently | Yes, sedative/GABA effects | | Vaginal discharge / irritation | Dryness / thin mucus | Heavy discharge, soreness | | Bloating | Mild | Moderate, smooth-muscle relaxation | | Breast tenderness | Mild | Moderate to significant | | Fatigue / drowsiness | Mild | Moderate (allopregnanolone) | | Visual disturbances | 1-2% (stop drug) | No | | Ovarian cysts / enlargement | ~14% of cycles | No | | Multiple pregnancy risk | 5-8% twin rate | No independent risk | | Uterine cramping | Occasional | Occasional |

Who Is Each Drug Right For (and Not Right For)?

Clomiphene Is Typically Right For

Women with anovulation or oligo-ovulation who are trying to conceive naturally or with IUI. This includes many women with PCOS, hypothalamic amenorrhea (with caution), or unexplained infertility in their reproductive years (generally under 40, though used beyond that). ASRM practice guidelines support clomiphene as a first-line oral agent for ovulation induction, though letrozole is now preferred for PCOS specifically because of the superior live-birth data from the PPCOSPP trial.

Clomiphene Is Not Right For

Women with already thin uterine lining on monitoring. Women with active ovarian cysts. Women who have not responded to three to six cycles of clomiphene (so-called clomiphene resistance, seen in up to 25% of women with PCOS). Women with unexplained infertility aged 38 or older, where moving directly to IVF may be more appropriate. Clomiphene should not be used in women with liver disease, given hepatic metabolism.

Vaginal Progesterone Is Typically Right For

Any woman undergoing IVF or frozen embryo transfer, where the luteal phase is pharmacologically dependent on exogenous hormone support. Women with a documented short luteal phase. Women with recurrent pregnancy loss associated with low progesterone (though the evidence for supplementation in this group is more nuanced). Women doing IUI with ovulation induction.

Vaginal Progesterone Is Not Right For

Women with unexplained infertility and normal ovulatory cycles who are not in a medically monitored treatment cycle. Progesterone supplementation in the absence of a clinical indication has not been shown to improve live-birth rates in natural cycles, and the PRISM trial (The Lancet, 2019) found no benefit of vaginal progesterone in unselected women with threatened miscarriage, though a subgroup with prior miscarriage did show a signal.

Pregnancy and Lactation Safety (Required Reading)

Clomiphene: Pregnancy Safety

Stop clomiphene as soon as pregnancy is confirmed. Clomiphene is FDA Pregnancy Category X, meaning animal and human data suggest fetal risk that outweighs any potential benefit. Studies showing neural tube defects and other fetal anomalies are not conclusive, but the precautionary standard is clear. Clomiphene has a long half-life (approximately five to seven days for the parent compound, with active metabolites persisting for weeks), so the potential for early fetal exposure before a pregnancy is confirmed exists. Your prescriber should give you a clear protocol for pregnancy testing before each cycle.

Clomiphene should not be used as a contraceptive and does not provide contraception. Women who are not actively trying to conceive but are prescribed clomiphene for other reasons (which is off-label and uncommon) need reliable contraception.

Lactation: Clomiphene suppresses lactation by its anti-estrogenic mechanism. It is not used postpartum in breastfeeding women.

Vaginal Progesterone: Pregnancy Safety

Vaginal micronized progesterone is generally continued through the first trimester when prescribed for luteal support or recurrent pregnancy loss support. ACOG supports progesterone supplementation in pregnancies achieved through ART and in singleton pregnancies with a prior preterm birth (for 17-hydroxyprogesterone caproate or vaginal progesterone for cervical length indications). Bioidentical micronized progesterone is not the same as the synthetic progestins implicated in historical safety concerns. No increased risk of fetal anomalies has been established with vaginal micronized progesterone.

Progesterone is present in breast milk naturally, and small amounts of supplemental progesterone may transfer. Luteal-phase vaginal progesterone is not typically used during lactation because its indication (supporting implantation and early pregnancy) does not apply postpartum.

How Hormone Status and Life Stage Shape Your Response

Reproductive Years (20s-Early 30s)

Women in this group with regular ovulatory cycles are unlikely to need clomiphene at all. Luteal-phase support becomes relevant in assisted reproduction contexts. Side effects tend to be tolerated well, but mood effects from both drugs deserve monitoring.

PCOS

Clomiphene resistance is a real phenomenon. Up to 20-25% of women with PCOS do not ovulate on clomiphene, and the drug's anti-estrogenic effect on the endometrium may compound the already complicated endometrial environment in PCOS. The PPCOSPP trial published in NEJM in 2014 randomized 750 women with PCOS and found ovulation in approximately 73% of letrozole-treated cycles compared with similar rates for clomiphene, but live births of 27.5% versus 19.1% favored letrozole. Many PCOS treatment protocols now pair letrozole (not clomiphene) with vaginal progesterone for luteal support in IUI cycles.

Late Reproductive Years (Late 30s-Early 40s)

Ovarian reserve declines, and the window for ovulation induction is narrower. Hot-flush side effects from clomiphene may be more pronounced if perimenopause is beginning. Clinicians often move to gonadotropins or IVF more quickly in this group. Vaginal progesterone remains part of IVF protocol regardless of age.

After Recurrent Pregnancy Loss

This is a group where both drugs may be used sequentially. Clomiphene or letrozole for ovulation induction, followed by vaginal progesterone in the luteal phase. The evidence for progesterone in this group is the subject of active research. The PROMISE trial (The Lancet, 2015) found no statistically significant benefit of luteal progesterone supplementation in unselected women with unexplained recurrent miscarriage, though the PRISM trial's subgroup analysis does show a signal in those with three or more prior losses.

Can You Switch from Clomid to Something Else?

Switching from clomiphene is common and well-supported. Letrozole (Femara) has largely replaced clomiphene as the first-line agent for women with PCOS, per ASRM's 2023 PCOS guideline. If you are tolerating clomiphene poorly because of hot flushes, mood symptoms, or thin cervical mucus, your clinician may switch you to letrozole, which does not carry the same anti-estrogenic effects on the endometrium and cervix.

A practical decision framework for the side-effect-driven switch:

• Hot flushes intolerable: Consider letrozole, which acts peripherally and avoids central estrogen-receptor blockade.
• Thin cervical mucus documented on ultrasound or monitoring: Letrozole, or add low-dose estrogen supplementation in the follicular phase (off-label, discuss with your RE).
• Mood effects significant: Discuss timing, dose reduction, or letrozole switch with your clinician.
• Vaginal discharge from progesterone is primary complaint: Ask about switching gel formulation to insert (Endometrin) or vice versa, since formulation affects discharge volume. Some clinicians use twice-daily dosing of a lower-residue insert over once-daily gel.
• Fatigue from progesterone: Scheduling doses at night may reduce functional impairment from sedation.

A Note on the Evidence Gap

Women have historically been under-represented in reproductive pharmacology trials, particularly for patient-reported outcomes like mood, quality of life, and side-effect burden. Most of the trial data from the Cochrane review on luteal support tracked live-birth rates as the primary outcome. Side effects were a secondary or tertiary concern. The Cochrane review itself flagged inconsistent adverse-event reporting across included trials.

This means the side-effect frequencies cited in this article for progesterone come primarily from prescribing information and small observational studies. For clomiphene, the PPCOSPP trial captured some adverse events but was not powered or designed to compare tolerability profiles in detail. When your clinician says "most women tolerate this well," they are often extrapolating from efficacy trials. Your lived experience of side effects is valid data that is systematically under-collected.